Description: Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Home Page: www.enanta.com
ENTA Technical Analysis
500 Arsenal Street
Watertown,
MA
02472
United States
Phone:
617 607 0800
Officers
| Name | Title |
|---|---|
| Dr. Jay R. Luly | Pres, CEO & Director |
| Mr. Paul J. Mellett Jr. | Sr. VP of Fin. & Admin. and CFO |
| Dr. Yat Sun Or Ph.D. | Sr. VP of R&D and Chief Scientific Officer |
| Ms. Tara Lynn Kieffer Ph.D. | Sr. VP of New Product Strategy & Devel. |
| Mr. Brendan Luu | Sr. VP of Bus. Devel. |
| Ms. Jennifer Viera | Sr. Director of Investor Relations & Corp. Communications |
| Mr. Nathaniel S. Gardiner J.D. | Sr. VP, Gen. Counsel & Sec. |
| Dr. Nathalie Adda M.D. | Consultant |
| Dr. Scott T. Rottinghaus | Sr. VP & Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8795 |
| Price-to-Sales TTM: | 10.5822 |
| IPO Date: | 2013-03-21 |
| Fiscal Year End: | September |
| Full Time Employees: | 160 |